Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

06 Jul 2024
Antibiotic and antiviral therapy in COVID-19 patients: Updates from ESCMID Global 2024

In COVID-19 patients, antibiotic therapy should be reserved only for suspected bacterial superinfections.

However, international data from over 1 million hospitalized COVID-19 patients across 65 countries showed that antibiotics were commonly prescribed empirically despite the low rates of reported bacterial co-infection.1

Reference
1. Dona D, et al. Antibiotic use, co-infections, antimicrobial resistance and clinical outcomes in COVID-19 patients hospitalized across 64 countries worldwide. Poster P0588. Presented at ESCMID Global 2024. Barcelona, Spain, 27-30 April 2024.

Resources

Antibiotic and antiviral therapy in COVID-19 patients – Updates from ESCMID Global 2024

Antibiotic and antiviral therapy in COVID-19 patients – Updates from ESCMID Global 2024

Antibiotic and antiviral therapy in COVID-19 patients – Updates from ESCMID Global 2024

Antibiotic and antiviral therapy in COVID-19 patients – Updates from ESCMID Global 2024